Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Abstract Background Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–targeting antibodies have been evaluated, largely in patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen M. Hewitt, Jeffrey Schlom, Raffit Hassan, James L. Gulley
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019-10-01
Colecção:Journal for ImmunoTherapy of Cancer
Assuntos:
Thymoma
Immunotherapy
Avelumab
Immune-related adverse events
Immunosuppressive therapy
Anti-PD-L1
Acesso em linha:http://link.springer.com/article/10.1186/s40425-019-0723-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados